Phase I Clinical Trial to Evaluate the Safety, Tolerance, and Exploratory Efficacy of ADSTEM Inj. in Patients With Moderate to Severe, Subacute and Chronic Atopic Dermatitis

Trial Profile

Phase I Clinical Trial to Evaluate the Safety, Tolerance, and Exploratory Efficacy of ADSTEM Inj. in Patients With Moderate to Severe, Subacute and Chronic Atopic Dermatitis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Autologous stem cell therapy (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors EHL Bio
  • Most Recent Events

    • 17 Aug 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
    • 17 Aug 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.
    • 21 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top